PE20220371A1 - PROCEDIMIENTO NOVEDOSO PARA LA PURIFICACION DE rHU-GCSF - Google Patents
PROCEDIMIENTO NOVEDOSO PARA LA PURIFICACION DE rHU-GCSFInfo
- Publication number
- PE20220371A1 PE20220371A1 PE2022000247A PE2022000247A PE20220371A1 PE 20220371 A1 PE20220371 A1 PE 20220371A1 PE 2022000247 A PE2022000247 A PE 2022000247A PE 2022000247 A PE2022000247 A PE 2022000247A PE 20220371 A1 PE20220371 A1 PE 20220371A1
- Authority
- PE
- Peru
- Prior art keywords
- rhu
- gcsf
- purification
- novel procedure
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Referida a una composicion farmaceutica, que comprende factor estimulante de colonias de granulocitos (G-CSF) en una formulacion intravascular (I.V.) parenteral liquida con excipientes farmaceuticamente aceptables para la proliferacion y diferenciacion de granulocitos
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2289MU2014 | 2014-07-14 | ||
PCT/IN2015/050066 WO2016009451A2 (en) | 2014-07-14 | 2015-07-13 | A novel process for purification of rhu-gcsf |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20220371A1 true PE20220371A1 (es) | 2022-03-16 |
Family
ID=55079140
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000247A PE20220371A1 (es) | 2014-07-14 | 2015-07-13 | PROCEDIMIENTO NOVEDOSO PARA LA PURIFICACION DE rHU-GCSF |
PE2017000070A PE20170769A1 (es) | 2014-07-14 | 2015-07-13 | Procedimiento novedoso para la purificacion de rhu-gcsf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017000070A PE20170769A1 (es) | 2014-07-14 | 2015-07-13 | Procedimiento novedoso para la purificacion de rhu-gcsf |
Country Status (13)
Country | Link |
---|---|
US (1) | US10519209B2 (es) |
EP (1) | EP3169697A4 (es) |
JP (1) | JP6742300B2 (es) |
AU (1) | AU2015291123C1 (es) |
BR (1) | BR112017000704A2 (es) |
CL (1) | CL2017000087A1 (es) |
CO (1) | CO2017001387A2 (es) |
EA (1) | EA035448B1 (es) |
MX (1) | MX2017000467A (es) |
NZ (1) | NZ728662A (es) |
PE (2) | PE20220371A1 (es) |
SA (1) | SA517380723B1 (es) |
WO (1) | WO2016009451A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102020995B1 (ko) * | 2017-10-30 | 2019-09-16 | 한국코러스 주식회사 | 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법 |
CN109840410B (zh) * | 2017-12-28 | 2021-09-21 | 中国科学院计算技术研究所 | 一种进程内数据隔离与保护的方法和系统 |
KR102140531B1 (ko) * | 2018-08-07 | 2020-08-04 | (주)휴온스 | Gly-Tβ4의 제조방법 |
EP3959222A4 (en) * | 2019-04-24 | 2023-06-14 | Tanvex Biopharma Usa, Inc. | METHOD FOR PRODUCTION OF GRANULOCYTE COLONY STIMULATING FACTOR |
WO2022167886A1 (en) * | 2021-02-04 | 2022-08-11 | Intas Pharmaceuticals Ltd. | An improved peg-gcsf purification process having dual ufdf |
WO2022245259A1 (ru) * | 2021-05-18 | 2022-11-24 | Акционерное общество "ГЕНЕРИУМ" | Способ промышленной очистки ромиплостима |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ218336A (en) | 1985-12-09 | 1991-08-27 | Kirin Amgen Inc | Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf) |
JP2001510033A (ja) * | 1997-07-14 | 2001-07-31 | ボルダー バイオテクノロジー, インコーポレイテッド | 成長ホルモンおよび関連タンパク質の誘導体 |
US6653098B1 (en) * | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
FR2796071B1 (fr) | 1999-07-08 | 2001-09-07 | Hoechst Marion Roussel Inc | Procede de purification de facteur de stimulation de colonies de granulocytes |
CN1663962A (zh) * | 2004-03-01 | 2005-09-07 | 重庆富进生物医药有限公司 | 重组人粒细胞集落刺激因子及其化学修饰物的一步纯化工艺 |
JP2007277094A (ja) * | 2004-06-29 | 2007-10-25 | Chemo Sero Therapeut Res Inst | 改変ダニ主要アレルゲン含有医薬組成物 |
DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
EP2044118A2 (en) * | 2006-06-13 | 2009-04-08 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
WO2008096370A2 (en) | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
US7625555B2 (en) * | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
DK2341061T3 (da) * | 2009-12-31 | 2013-11-04 | Arven Ilac Sanayi Ve Ticaret As | Ny fremgangsmåde til fremstilling af G-CSF (granulocytkoloni-stimulerende faktor) |
CN102234310B (zh) | 2010-04-30 | 2017-02-08 | 杭州九源基因工程有限公司 | 一种聚乙二醇修饰蛋白的分离纯化方法 |
RU2446173C1 (ru) | 2010-08-13 | 2012-03-27 | Зао "Биокад" | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
KR101831300B1 (ko) | 2010-10-29 | 2018-02-23 | 한미사이언스 주식회사 | 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법 |
CN102485742A (zh) | 2010-12-02 | 2012-06-06 | 山东新时代药业有限公司 | 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法 |
WO2012106463A2 (en) * | 2011-02-01 | 2012-08-09 | Fate Therapeutics, Inc. | Cardiotrophin related molecules for enhanced therapeutics |
US9422354B2 (en) * | 2012-06-19 | 2016-08-23 | Indian Institute Of Technology Delhi | Process for purification of recombinant granulocyte colony stimulating factor (rHu GCSF) |
-
2015
- 2015-07-13 EP EP15822758.7A patent/EP3169697A4/en active Pending
- 2015-07-13 US US15/326,277 patent/US10519209B2/en active Active
- 2015-07-13 JP JP2017502883A patent/JP6742300B2/ja active Active
- 2015-07-13 PE PE2022000247A patent/PE20220371A1/es unknown
- 2015-07-13 PE PE2017000070A patent/PE20170769A1/es unknown
- 2015-07-13 BR BR112017000704A patent/BR112017000704A2/pt active Search and Examination
- 2015-07-13 AU AU2015291123A patent/AU2015291123C1/en active Active
- 2015-07-13 MX MX2017000467A patent/MX2017000467A/es unknown
- 2015-07-13 NZ NZ728662A patent/NZ728662A/en unknown
- 2015-07-13 WO PCT/IN2015/050066 patent/WO2016009451A2/en active Application Filing
- 2015-07-13 EA EA201700058A patent/EA035448B1/ru unknown
-
2017
- 2017-01-12 CL CL2017000087A patent/CL2017000087A1/es unknown
- 2017-01-14 SA SA517380723A patent/SA517380723B1/ar unknown
- 2017-02-13 CO CONC2017/0001387A patent/CO2017001387A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3169697A2 (en) | 2017-05-24 |
CO2017001387A2 (es) | 2017-05-10 |
BR112017000704A2 (pt) | 2017-11-14 |
NZ728662A (en) | 2021-01-29 |
AU2015291123B2 (en) | 2020-03-12 |
EA035448B1 (ru) | 2020-06-17 |
WO2016009451A2 (en) | 2016-01-21 |
US10519209B2 (en) | 2019-12-31 |
PE20170769A1 (es) | 2017-07-04 |
EP3169697A4 (en) | 2017-11-08 |
US20170210784A1 (en) | 2017-07-27 |
SA517380723B1 (ar) | 2021-05-18 |
MX2017000467A (es) | 2017-07-28 |
AU2015291123C1 (en) | 2020-12-10 |
EA201700058A1 (ru) | 2017-07-31 |
WO2016009451A3 (en) | 2016-05-19 |
CL2017000087A1 (es) | 2018-05-18 |
JP6742300B2 (ja) | 2020-08-19 |
JP2017526649A (ja) | 2017-09-14 |
AU2015291123A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20220371A1 (es) | PROCEDIMIENTO NOVEDOSO PARA LA PURIFICACION DE rHU-GCSF | |
MY191574A (en) | Pharmaceutical compositions comprising meloxicam | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
CL2015000784A1 (es) | Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades. | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
NZ739588A (en) | Enhanced stability of novel liquid compositions | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
PH12016500985A1 (en) | Use of benzimidazole-proline derivatives | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
IN2013MU00711A (es) | ||
WO2014153495A9 (en) | Novel stat3 inhibitors | |
IN2013MU03583A (es) | ||
HK1222325A1 (zh) | 高效的胰酶藥物組合物 | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
IN2013MU01985A (es) | ||
WO2015082590A3 (en) | Bis-mmf derivatives | |
AU356195S (en) | Shelving unit | |
WO2014122460A3 (en) | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes | |
MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
WO2015181837A3 (en) | Novel compounds as anti-tubercular agents |